ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said the first patient in the Phase Ib/II clinical trial of IMM2510 in combination with chemotherapy for the first-line treatment of non-small cell lung cancer was successfully dosed, according to a Monday filing with the Hong Kong bourse.
IMM2510 is a bispecific molecule developed by the group that uses a mAbTrap structure to target two proteins: VEGF, which promotes blood vessel growth, and PD-L1, which suppresses the immune system, reducing blood flow to tumors and leads to their shrinking, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。